Skip to main content

CAR-T Therapies Specialty Channel

Featured Article
Chimeric antigen receptor T-cell therapy is effective in a certain group of patients with B-cell acute lymphoblastic leukemia.
Researchers may have found the reason some patients with advanced CLL do not respond to chimeric antigen receptor T-cell therapy.
U.S. regulators approved Novartis’ cell therapy Kymriah for treatment of patients with a second type of blood cancer.
Expert Insights
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong,…
Steve Miller, CMO, discusses his thoughts on the recently approved gene therapy for acute lymphoblastic leukemia.